Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Sonoma Pharmaceuticals, Inc. (SNOA) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1.28, with a market capitalisation of $6.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.85 to $4.60. This page covers its latest market performance, valuation, price trends and company information.
$6.18M | |
$1.29 | |
$1,484.59 | |
$0.85 | |
$1.29 | |
69.48K | |
150.23K | |
-- | |
$4.60 | |
$0.85 | |
-- | |
-- |
Sonoma Pharmaceuticals, Inc. (SNOA) is trading at $1.29 in pre-market trading as of 2026-09-15 23:31:00, down 0.31% ($0.00) from the previous close of $1.29
Pre-market trading shows how investors are pricing SNOA before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Sonoma Pharmaceuticals, Inc. (SNOA) moved from $1.33 to $1.28, representing a decline of 3.40% ($0.04).
The stock traded between $1.27 and $1.36 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 45.34 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.5%
SNOA is currently trading at $1.28, placing it 11.5% of the way from its 52-week low of $0.85 to its 52-week high of $4.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sonoma Pharmaceuticals, Inc. (SNOA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.